Kiertscher SM - Search Results

1

Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment.

Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD. Liau LM, et al. Among authors: kiertscher sm. Clin Cancer Res. 2005 Aug 1;11(15):5515-25. doi: 10.1158/1078-0432.CCR-05-0464. Clin Cancer Res. 2005. PMID: 16061868 Clinical Trial.

2

Granulocyte/macrophage-colony stimulating factor and interleukin-4 expand and activate type-1 dendritic cells (DC1) when administered in vivo to cancer patients.

Kiertscher SM, Gitlitz BJ, Figlin RA, Roth MD. Kiertscher SM, et al. Int J Cancer. 2003 Nov 1;107(2):256-61. doi: 10.1002/ijc.11379. Int J Cancer. 2003. PMID: 12949803 Clinical Trial.

3

Modifying adenoviral vectors for use as gene-based cancer vaccines.

Basak SK, Kiertscher SM, Harui A, Roth MD. Basak SK, et al. Among authors: kiertscher sm. Viral Immunol. 2004;17(2):182-96. doi: 10.1089/0882824041310603. Viral Immunol. 2004. PMID: 15279698 Review.

4

Reconstitution of huPBL-NSG mice with donor-matched dendritic cells enables antigen-specific T-cell activation.

Harui A, Kiertscher SM, Roth MD. Harui A, et al. Among authors: kiertscher sm. J Neuroimmune Pharmacol. 2011 Mar;6(1):148-57. doi: 10.1007/s11481-010-9223-x. Epub 2010 Jun 8. J Neuroimmune Pharmacol. 2011. PMID: 20532647 Free PMC article.

5

Exposure to Δ9-Tetrahydrocannabinol Impairs the Differentiation of Human Monocyte-derived Dendritic Cells and their Capacity for T cell Activation.

Roth MD, Castaneda JT, Kiertscher SM. Roth MD, et al. Among authors: kiertscher sm. J Neuroimmune Pharmacol. 2015 Jun;10(2):333-43. doi: 10.1007/s11481-015-9587-z. Epub 2015 Jan 23. J Neuroimmune Pharmacol. 2015. PMID: 25614186 Free PMC article.

6

Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.

Mulders P, Tso CL, Gitlitz B, Kaboo R, Hinkel A, Frand S, Kiertscher S, Roth MD, deKernion J, Figlin R, Belldegrun A. Mulders P, et al. Clin Cancer Res. 1999 Feb;5(2):445-54. Clin Cancer Res. 1999. PMID: 10037196

7

Human CD14+ leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4.

Kiertscher SM, Roth MD. Kiertscher SM, et al. J Leukoc Biol. 1996 Feb;59(2):208-18. doi: 10.1002/jlb.59.2.208. J Leukoc Biol. 1996. PMID: 8603993

8

Granulocyte macrophage colony-stimulating factor and interleukin 4 enhance the number and antigen-presenting activity of circulating CD14+ and CD83+ cells in cancer patients.

Roth MD, Gitlitz BJ, Kiertscher SM, Park AN, Mendenhall M, Moldawer N, Figlin RA. Roth MD, et al. Among authors: kiertscher sm. Cancer Res. 2000 Apr 1;60(7):1934-41. Cancer Res. 2000. PMID: 10766183 Clinical Trial.

9

Helper-dependent adenoviral vectors efficiently express transgenes in human dendritic cells but still stimulate antiviral immune responses.

Roth MD, Cheng Q, Harui A, Basak SK, Mitani K, Low TA, Kiertscher SM. Roth MD, et al. Among authors: kiertscher sm. J Immunol. 2002 Oct 15;169(8):4651-6. doi: 10.4049/jimmunol.169.8.4651. J Immunol. 2002. PMID: 12370405

10

Phase I trial of granulocyte macrophage-colony stimulating factor and interleukin-4 as a combined immunotherapy for patients with cancer.

Gitlitz BJ, Figlin RA, Kiertscher SM, Moldawer N, Rosen F, Roth MD. Gitlitz BJ, et al. Among authors: kiertscher sm. J Immunother. 2003 Mar-Apr;26(2):171-8. doi: 10.1097/00002371-200303000-00010. J Immunother. 2003. PMID: 12616109 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25 results

Search Page

Filters